Cargando…
Der Einsatz von Immuncheckpoint-Inhibitoren im onkologischen Alltag
BACKGROUND: The advent of immune checkpoint inhibitors has dramatically changed the treatment landscape of many different tumor types. In the clinical routine, humanized antibodies against the immune checkpoints cytotoxic T‑lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1/program...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653782/ https://www.ncbi.nlm.nih.gov/pubmed/32936368 http://dx.doi.org/10.1007/s00393-020-00876-2 |